Editorial Board

Open Access Journal of Mycology & Mycological Sciences

Home OAJMMS Editorial Board Liu Zhenjiang

Share this profile

LinkedIn Twitter / X

✓ Link copied!

LZ

Liu Zhenjiang

Editorial Board Member
Grit Biotechnology China Member since 2022

Biography

Utilizing immunotherapy to improve the outcomes of patients who are suffering from cancer is at the heart of what a cancer-immunologist is trying to achieve. Since Prof. Steven Rosenberg introduced a totally new possibility by one NEJM publication in 1986, different research groups all over the world are working under the ideas of immunotherapy and come with great successes in different subareas of immunotherapy: adoptive cellular treatment (ACT), cancer vaccine and Immune checkpoint inhibitors (ICB). This smoking hot area is what I believe as the future of cancer treatment and I would put my life and energy into this trend without a second thought.

Research Interests

Expansion of Tumor-reactive T Cells/TCRs from patients with Cancer Adoptive T-cell therapy in different cancers Tumor immunotherapy including adoptive cell therapy Immune checkpoint Blockade Cancer Vaccine Tumor specific TCR sequencing Predictive markers for cancer immunotherapy

Other Editorial Board Members

Submit Manuscript

Chat with us on WhatsApp

Welcome to Medwin Publishers. How can we help you today?